Trilaciclib plus chemo for certain solid tumors
Part of Cancer clinical trials.
This trial tests trilaciclib, a drug that may protect healthy cells during chemotherapy, in people with solid tumors that depend on CDK4/6 proteins. The goal is to see if it helps reduce side effects when given before chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that is driven by CDK4/6 proteins
- Your doctor decides you need trilaciclib as a first prevention (based on a special model)
- You are not already taking trilaciclib for a different reason
- You are able to receive chemotherapy as part of your treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called trilaciclib, given before chemotherapy to protect your bone marrow (where blood cells are made). It is for people with advanced bile duct or pancreatic cancer who are about to start chemotherapy.
This trial tests a drug called trilaciclib, given along with standard chemotherapy (etoposide plus cisplatin or carboplatin) and radiation. The goal is to see if trilaciclib can help protect your bone marrow from the side effects of treatment.
This trial tests a drug called trilaciclib that may protect your bone marrow during chemotherapy. It is for people with several types of advanced solid tumors who will receive a specific chemo combination (paclitaxel plus carboplatin) for the first time.
This trial tests whether adding trilaciclib to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. It’s for patients who are starting treatment for the first time and can safely receive pre-surgery chemotherapy.
This trial tests a new drug combination for people with locally advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if adding trilaciclib to standard chemo and immunotherapy works better before surgery.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
Hear when a new Trilaciclib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.